{"resourceType":"ClinicalUseDefinition","id":"example-interaction","text":{"status":"extensions","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative: ClinicalUseDefinition\u003c/b\u003e\u003ca name\u003d\"example-interaction\"\u003e \u003c/a\u003e\u003c/p\u003e\u003cdiv style\u003d\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"\u003e\u003cp style\u003d\"margin-bottom: 0px\"\u003eResource ClinicalUseDefinition \u0026quot;example-interaction\u0026quot; \u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u003cb\u003eStructureDefinition Work Group\u003c/b\u003e: brr\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: interaction\u003c/p\u003e\u003cp\u003e\u003cb\u003esubject\u003c/b\u003e: \u003ca href\u003d\"medicinalproductdefinition-example.html\"\u003eMedicinalProductDefinition/example\u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003einteraction\u003c/b\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003einteractant\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eitem\u003c/b\u003e: alphaconazole \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (interactant#alphaconazole)\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003einteractant\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003eitem\u003c/b\u003e: betaconazole \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (interactant#betaconazole)\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: Inhibitor \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (interactionsType#Inhibitor)\u003c/span\u003e\u003c/p\u003e\u003ch3\u003eEffects\u003c/h3\u003e\u003ctable class\u003d\"grid\"\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eConcept\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e*\u003c/td\u003e\u003ctd\u003eIncreased plasma concentration \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e ()\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003cp\u003e\u003cb\u003emanagement\u003c/b\u003e: Careful monitoring of dose \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e ()\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003c/div\u003e"},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"brr"}],"type":"interaction","subject":[{"reference":"MedicinalProductDefinition/example"}],"interaction":{"interactant":[{"itemCodeableConcept":{"coding":[{"system":"http://ema.europa.eu/example/interactant","code":"alphaconazole"}]}},{"itemCodeableConcept":{"coding":[{"system":"http://ema.europa.eu/example/interactant","code":"betaconazole"}]}}],"type":{"coding":[{"system":"http://ema.europa.eu/example/interactionsType","code":"Inhibitor"}]},"effect":{"concept":{"text":"Increased plasma concentration"}},"management":[{"text":"Careful monitoring of dose"}]}}
{"resourceType":"ClinicalUseDefinition","id":"example-indication","text":{"status":"extensions","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative: ClinicalUseDefinition\u003c/b\u003e\u003ca name\u003d\"example-indication\"\u003e \u003c/a\u003e\u003c/p\u003e\u003cdiv style\u003d\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"\u003e\u003cp style\u003d\"margin-bottom: 0px\"\u003eResource ClinicalUseDefinition \u0026quot;example-indication\u0026quot; \u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u003cb\u003eStructureDefinition Work Group\u003c/b\u003e: brr\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: indication\u003c/p\u003e\u003cp\u003e\u003cb\u003esubject\u003c/b\u003e: \u003ca href\u003d\"medicinalproductdefinition-example.html\"\u003eMedicinalProductDefinition/example\u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eindication\u003c/b\u003e\u003c/p\u003e\u003ch3\u003eDiseaseSymptomProcedures\u003c/h3\u003e\u003ctable class\u003d\"grid\"\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eConcept\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e*\u003c/td\u003e\u003ctd\u003ePrevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults. \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (indicationasdisease-symptom-procedure#Pulmonary-embolism-and-thrombosis-example-code)\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003ch3\u003eDiseaseStatuses\u003c/h3\u003e\u003ctable class\u003d\"grid\"\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eConcept\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e*\u003c/td\u003e\u003ctd\u003eRecurrent \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (diseasestatus#Recurrent)\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003ch3\u003eIntendedEffects\u003c/h3\u003e\u003ctable class\u003d\"grid\"\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eConcept\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e*\u003c/td\u003e\u003ctd\u003ePRYLX \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (intendedeffect#PRYLX)\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003cp\u003e\u003cb\u003epopulation\u003c/b\u003e: \u003ca name\u003d\"group\"\u003e \u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp/\u003e\u003cp\u003e\u003ca name\u003d\"group\"\u003e \u003c/a\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: person\u003c/p\u003e\u003cp\u003e\u003cb\u003emembership\u003c/b\u003e: definitional\u003c/p\u003e\u003ch3\u003eCharacteristics\u003c/h3\u003e\u003ctable class\u003d\"grid\"\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eCode\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eValue[x]\u003c/b\u003e\u003c/td\u003e\u003ctd\u003e\u003cb\u003eExclude\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e*\u003c/td\u003e\u003ctd\u003eage-range \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (characteristic#age-range)\u003c/span\u003e\u003c/td\u003e\u003ctd\u003e18-? a\u003c/td\u003e\u003ctd\u003efalse\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003c/div\u003e"},"contained":[{"resourceType":"Group","id":"group","type":"person","membership":"definitional","characteristic":[{"code":{"coding":[{"system":"http://ema.europa.eu/example/characteristic","code":"age-range"}]},"valueRange":{"low":{"value":18,"unit":"a"}},"exclude":false}]}],"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"brr"}],"type":"indication","subject":[{"reference":"MedicinalProductDefinition/example"}],"indication":{"diseaseSymptomProcedure":{"concept":{"coding":[{"system":"http://ema.europa.eu/example/indicationasdisease-symptom-procedure","code":"Pulmonary-embolism-and-thrombosis-example-code"}],"text":"Prevention of venous thromboembolic events (VTE) in adult patients who have undergone elective hip or knee replacement surgery. Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (NVAF), with one or more risk factors, such as prior stroke or transient ischaemic attack (TIA); age ≥ 75 years; hypertension; diabetes mellitus; symptomatic heart failure (NYHA Class ≥ II). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults."}},"diseaseStatus":{"concept":{"coding":[{"system":"http://ema.europa.eu/example/diseasestatus","code":"Recurrent"}]}},"intendedEffect":{"concept":{"coding":[{"system":"http://ema.europa.eu/example/intendedeffect","code":"PRYLX"}]}}},"population":[{"reference":"#group"}]}
{"resourceType":"ClinicalUseDefinition","id":"example-warning","text":{"status":"extensions","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative: ClinicalUseDefinition\u003c/b\u003e\u003ca name\u003d\"example-warning\"\u003e \u003c/a\u003e\u003c/p\u003e\u003cdiv style\u003d\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"\u003e\u003cp style\u003d\"margin-bottom: 0px\"\u003eResource ClinicalUseDefinition \u0026quot;example-warning\u0026quot; \u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u003cb\u003eStructureDefinition Work Group\u003c/b\u003e: brr\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: warning\u003c/p\u003e\u003cp\u003e\u003cb\u003ecategory\u003c/b\u003e: Effects on Ability to Drive and Use Machines \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (\u003ca href\u003d\"codesystem-clinical-use-definition-category.html\"\u003eClinical Use Definition Category\u003c/a\u003e#DriveAndMachines)\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003esubject\u003c/b\u003e: \u003ca href\u003d\"medicinalproductdefinition-example.html\"\u003eMedicinalProductDefinition/example\u003c/a\u003e\u003c/p\u003e\u003ch3\u003eWarnings\u003c/h3\u003e\u003ctable class\u003d\"grid\"\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eDescription\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e*\u003c/td\u003e\u003ctd\u003eMay cause drowsiness. Avoid driving or operating heavy machinery.\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/div\u003e"},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"brr"}],"type":"warning","category":[{"coding":[{"system":"http://hl7.org/fhir/clinical-use-definition-category","code":"DriveAndMachines","display":"Effects on Ability to Drive and Use Machines"}]}],"subject":[{"reference":"MedicinalProductDefinition/example"}],"warning":{"description":"May cause drowsiness. Avoid driving or operating heavy machinery."}}
{"resourceType":"ClinicalUseDefinition","id":"example","text":{"status":"extensions","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative: ClinicalUseDefinition\u003c/b\u003e\u003ca name\u003d\"example\"\u003e \u003c/a\u003e\u003c/p\u003e\u003cdiv style\u003d\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"\u003e\u003cp style\u003d\"margin-bottom: 0px\"\u003eResource ClinicalUseDefinition \u0026quot;example\u0026quot; \u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u003cb\u003eStructureDefinition Work Group\u003c/b\u003e: brr\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: contraindication\u003c/p\u003e\u003cp\u003e\u003cb\u003esubject\u003c/b\u003e: \u003ca href\u003d\"medicinalproductdefinition-example.html\"\u003eMedicinalProductDefinition/example\u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003econtraindication\u003c/b\u003e\u003c/p\u003e\u003ch3\u003eDiseaseSymptomProcedures\u003c/h3\u003e\u003ctable class\u003d\"grid\"\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eConcept\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e*\u003c/td\u003e\u003ctd\u003eHepatic disease associated with coagulopathy and clinically relevant bleeding risk \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (contraindicationsasdisease-symptom-procedure#hepatic-example-code)\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003c/div\u003e"},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"brr"}],"type":"contraindication","subject":[{"reference":"MedicinalProductDefinition/example"}],"contraindication":{"diseaseSymptomProcedure":{"concept":{"coding":[{"system":"http://ema.europa.eu/example/contraindicationsasdisease-symptom-procedure","code":"hepatic-example-code"}],"text":"Hepatic disease associated with coagulopathy and clinically relevant bleeding risk"}}}}
{"resourceType":"ClinicalUseDefinition","id":"example-contraindication","text":{"status":"extensions","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative: ClinicalUseDefinition\u003c/b\u003e\u003ca name\u003d\"example-contraindication\"\u003e \u003c/a\u003e\u003c/p\u003e\u003cdiv style\u003d\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"\u003e\u003cp style\u003d\"margin-bottom: 0px\"\u003eResource ClinicalUseDefinition \u0026quot;example-contraindication\u0026quot; \u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u003cb\u003eStructureDefinition Work Group\u003c/b\u003e: brr\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: contraindication\u003c/p\u003e\u003cp\u003e\u003cb\u003esubject\u003c/b\u003e: \u003ca href\u003d\"medicinalproductdefinition-example.html\"\u003eMedicinalProductDefinition/example\u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003econtraindication\u003c/b\u003e\u003c/p\u003e\u003ch3\u003eDiseaseSymptomProcedures\u003c/h3\u003e\u003ctable class\u003d\"grid\"\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eConcept\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e*\u003c/td\u003e\u003ctd\u003eConcomitant treatment with any other anticoagulant agent \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e ()\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eotherTherapy\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003erelationshipType\u003c/b\u003e: Co-therapy(with) \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (therapyrelationshiptype#Co-therapy(with))\u003c/span\u003e\u003c/p\u003e\u003ch3\u003eTreatments\u003c/h3\u003e\u003ctable class\u003d\"grid\"\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eConcept\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e*\u003c/td\u003e\u003ctd\u003eOralanticoagulants \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (medication#Oralanticoagulants)\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eotherTherapy\u003c/b\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003erelationshipType\u003c/b\u003e: Co-therapy(with) \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (therapyrelationshiptype#Co-therapy(with))\u003c/span\u003e\u003c/p\u003e\u003ch3\u003eTreatments\u003c/h3\u003e\u003ctable class\u003d\"grid\"\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eConcept\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e*\u003c/td\u003e\u003ctd\u003eLowmolecularweightheparins \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (medication#Lowmolecularweightheparins)\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003c/blockquote\u003e\u003c/blockquote\u003e\u003c/div\u003e"},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"brr"}],"type":"contraindication","subject":[{"reference":"MedicinalProductDefinition/example"}],"contraindication":{"diseaseSymptomProcedure":{"concept":{"text":"Concomitant treatment with any other anticoagulant agent"}},"otherTherapy":[{"relationshipType":{"coding":[{"system":"http://ema.europa.eu/example/therapyrelationshiptype","code":"Co-therapy(with)"}]},"treatment":{"concept":{"coding":[{"system":"http://ema.europa.eu/example/medication","code":"Oralanticoagulants"}]}}},{"relationshipType":{"coding":[{"system":"http://ema.europa.eu/example/therapyrelationshiptype","code":"Co-therapy(with)"}]},"treatment":{"concept":{"coding":[{"system":"http://ema.europa.eu/example/medication","code":"Lowmolecularweightheparins"}]}}}]}}
{"resourceType":"ClinicalUseDefinition","id":"example-undesirable","text":{"status":"extensions","div":"\u003cdiv xmlns\u003d\"http://www.w3.org/1999/xhtml\"\u003e\u003cp\u003e\u003cb\u003eGenerated Narrative: ClinicalUseDefinition\u003c/b\u003e\u003ca name\u003d\"example-undesirable\"\u003e \u003c/a\u003e\u003c/p\u003e\u003cdiv style\u003d\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"\u003e\u003cp style\u003d\"margin-bottom: 0px\"\u003eResource ClinicalUseDefinition \u0026quot;example-undesirable\u0026quot; \u003c/p\u003e\u003c/div\u003e\u003cp\u003e\u003cb\u003eStructureDefinition Work Group\u003c/b\u003e: brr\u003c/p\u003e\u003cp\u003e\u003cb\u003etype\u003c/b\u003e: undesirable-effect\u003c/p\u003e\u003cp\u003e\u003cb\u003esubject\u003c/b\u003e: \u003ca href\u003d\"medicinalproductdefinition-example.html\"\u003eMedicinalProductDefinition/example\u003c/a\u003e\u003c/p\u003e\u003cblockquote\u003e\u003cp\u003e\u003cb\u003eundesirableEffect\u003c/b\u003e\u003c/p\u003e\u003ch3\u003eSymptomConditionEffects\u003c/h3\u003e\u003ctable class\u003d\"grid\"\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e-\u003c/td\u003e\u003ctd\u003e\u003cb\u003eConcept\u003c/b\u003e\u003c/td\u003e\u003c/tr\u003e\u003ctr\u003e\u003ctd style\u003d\"display: none\"\u003e*\u003c/td\u003e\u003ctd\u003eAnaemia \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (undesirableeffectassymptom-condition-effect#Anaemia)\u003c/span\u003e\u003c/td\u003e\u003c/tr\u003e\u003c/table\u003e\u003cp\u003e\u003cb\u003eclassification\u003c/b\u003e: Blood-and-lymphatic-system-disorders \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (symptom-condition-effectclassification#Blood-and-lymphatic-system-disorders)\u003c/span\u003e\u003c/p\u003e\u003cp\u003e\u003cb\u003efrequencyOfOccurrence\u003c/b\u003e: Common \u003cspan style\u003d\"background: LightGoldenRodYellow; margin: 4px; border: 1px solid khaki\"\u003e (frequencyofoccurrence#Common)\u003c/span\u003e\u003c/p\u003e\u003c/blockquote\u003e\u003c/div\u003e"},"extension":[{"url":"http://hl7.org/fhir/StructureDefinition/structuredefinition-wg","valueCode":"brr"}],"type":"undesirable-effect","subject":[{"reference":"MedicinalProductDefinition/example"}],"undesirableEffect":{"symptomConditionEffect":{"concept":{"coding":[{"system":"http://ema.europa.eu/example/undesirableeffectassymptom-condition-effect","code":"Anaemia"}]}},"classification":{"coding":[{"system":"http://ema.europa.eu/example/symptom-condition-effectclassification","code":"Blood-and-lymphatic-system-disorders"}]},"frequencyOfOccurrence":{"coding":[{"system":"http://ema.europa.eu/example/frequencyofoccurrence","code":"Common"}]}}}